Evidence map›Paper›PMID 33548798›Full record

ArticleCytokine2021

Prognostic bioindicators in severe COVID-19 patients.

L Bergantini, E Bargagli, M d'Alessandro, R M Refini, P Cameli, L Galasso, C Scapellato, F Montagnani, S Scolletta, F Franchi and 5 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cytokine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed, 2 pooled it
2.7field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 2 syntheses or guidelines pooled it, 45 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Observational
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. COVID-19-related hyperglycemia is associated with infection of hepatocytes and stimulation of gluconeogenesis.Proceedings of the National Academy of Sciences of the United States of America · 2023
    Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 1 institution in 1 country.

L BergantiniRespiratory Diseases and Lung Transplant Unit, Department of Medical and Surgical Sciences & Neurosciences, Siena University Hospital, Siena, Italy. Electronic address: laurabergantini@gmail.com.
E BargagliRespiratory Diseases and Lung Transplant Unit, Department of Medical and Surgical Sciences & Neurosciences, Siena University Hospital, Siena, Italy.
M d'AlessandroRespiratory Diseases and Lung Transplant Unit, Department of Medical and Surgical Sciences & Neurosciences, Siena University Hospital, Siena, Italy.
R M RefiniRespiratory Diseases and Lung Transplant Unit, Department of Medical and Surgical Sciences & Neurosciences, Siena University Hospital, Siena, Italy.
P CameliRespiratory Diseases and Lung Transplant Unit, Department of Medical and Surgical Sciences & Neurosciences, Siena University Hospital, Siena, Italy.
L GalassoClinical Pathology Unit, Innovation, Experimentation and Clinical and Translational Research Department, University Hospital of Siena, Siena, Italy.
C ScapellatoClinical Pathology Unit, Innovation, Experimentation and Clinical and Translational Research Department, University Hospital of Siena, Siena, Italy.
F MontagnaniDepartment of Medical Biotechnologies, University of Siena, Italy; Infectious and Tropical Diseases Unit, Department of Medical Science, Siena University Hospital, Italy.
S ScollettaAnaesthesia and Intensive Care Unit, Department of Medicine, Surgery and Neuroscience, University of Siena, Siena, Italy.
F FranchiAnaesthesia and Intensive Care Unit, Department of Medicine, Surgery and Neuroscience, University of Siena, Siena, Italy.
S ValenteDepartment of Cardiovascular Diseases, University of Siena, Siena, Italy.
D BennettRespiratory Diseases and Lung Transplant Unit, Department of Medical and Surgical Sciences & Neurosciences, Siena University Hospital, Siena, Italy.
G SebastianiDiabetes Unit, Department of Medicine, Surgery and Neurosciences, University of Siena and Fondazione Umberto Di Mario ONLUS-Toscana Life Science Park, Siena, Italy.
B FredianiRheumatology Unit, Department of Medical Sciences, Surgery and Neurosciences, University of Siena, Siena, Italy.
F DottaDiabetes Unit, Department of Medicine, Surgery and Neurosciences, University of Siena and Fondazione Umberto Di Mario ONLUS-Toscana Life Science Park, Siena, Italy.
University of Siena · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundSevere acute respiratory syndrome caused by novel coronavirus 2 (SARS-CoV-2) emerged in Wuhan (China) in December 2019. Here we evaluated a panel of biomarkers to phenotype patients and to define the role of immuno-inflammatory mediators as biomarkers of severity. MATERIALS AND

methodsSerum samples were obtained from 24 COVID-19 patients on admission to hospital, before any treatment or infusion of intravenous steroids or invasive ventilation. KL-6 IL-6 and C-peptide were measured by chemiluminescent enzyme immunoassay. IL-6 assay was validated for accuracy and precision. The validity of variables used to distinguish severe from mild-to-moderate patients was assessed by areas under curves (AUC) of the receiver operating characteristic (ROC) and logistic regression was performed to combine parameters of the two groups.

resultsIn the severe group, IL-6, CRP and KL-6 concentrations were significantly higher than in mild-to-moderate patients. KL-6, IL-6 and CRP concentrations were directly correlated with each other. ROC curve analysis of the logistic regression model including IL-6, KL-6 and CRP showed the best performance with an AUC of 0.95.

conclusionsBesides corroborating previous reports of over-expression of IL-6 in severe COVID-19 patients requiring mechanical ventilation, analytical determination of other mediators showed that IL-6 concentrations were correlated with those of KL-6 and CRP. The combination of these three prognostic bioindicators made it possible to distinguish severe COVID-19 patients with poor prognosis from mild-to-moderate patients.

Indexed as

PandemicsSARS-CoV-2AgedBiomarkersCase-Control StudiesCOVID-19C-PeptideC-Reactive ProteinCytokinesFemaleHumansInflammation MediatorsInterleukin-6ItalyMaleMiddle AgedBiomarkersC-PeptideC-Reactive ProteinCytokinesIL6 protein, humanInflammation MediatorsInterleukin-6MUC1 protein, humanMucin-1BiomarkersCOVID-19IL-6KL-6

Identifiers

PMID33548798
PMCPMC7843114
OpenAlexW3127250745

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.